60 Degrees Pharmaceuticals, Inc. Stock News

60 Degrees Pharmaceuticals has entered an agreement with Tufts Medical Center to conduct a clinical trial that will evaluate the safety and efficacy of tafenoquine for the treatment of babesiosis in h

60 Degrees Pharmaceuticals funds a study at NC State to test for Babesia spp in chronic fatigue patients, aiming to link these infections to CFS symptoms.

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP – Free Report) – HC Wainwright lowered their Q2 2024 earnings per share (EPS) estimates for 60 Degrees Pharmaceuticals in a research report is

Q1 2024 net product revenues increased 515% year-over-year to $105.7 thousand. Gross profit increased from ($55.9 thousand) to $51.0 thousand.

60 Degrees Pharma plans clinical trial of Tafenoquine for Babesiosis. Letter to Journal of Infectious Diseases outlines protocol. Enrollment starts summer.

Trial planning and execution to proceed as planned WASHINGTON, May 02, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.  (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company

60 Degrees Pharma (Nasdaq: SXTP) will sponsor a study using tafenoquine, an FDA-approved malaria drug, to treat canine babesiosis, a tick-borne disease.

60 Degrees Pharma advises of expected FDA response a month later than anticipated. Prepares for June 1, 2024, start of trial of tafenoquine for babesiosis.

Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitals Tafenoquine's presumed mode of action against C.

Kristen Landon appointed Chief Commercial Officer at 60 Degrees Pharma leading ARAKODA® relaunch for malaria prevention and expanded tick-borne strategy.

JERSEY CITY, N.J. , Jan. 31, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that 60 Degrees Pharmaceuticals,

WASHINGTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing n

PDD (NASDAQ: PDD ) stock is slipping on Tuesday after Morgan Stanley's analysts provided a sour look at the company's Temu e-commerce app. This new coverage comes from Morgan Stanley analysts Simeon G

JERSEY CITY, N.J. , Jan. 30, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that 60 Degrees Pharmaceuticals,

60 Degrees Pharma announces a $2.4 mil public offering, with funds to be used for working capital, relaunching ARAKODA for malaria prevention, and research